Dutch interest group calls for excessive drug-pricing probe
Credit: luchschen/iStock
An advocacy group has said it will ask the Netherlands’ competition authority to investigate a drugmaker for setting excessive prices for the only drug that is available on the market for treating a rare genetic disease.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now